Skip to content

Neurocrine Biosciences

US · NBIX #1162 by market cap Listed 1970
150.57 -6.02 -3.84%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Recent news

  • Rating change
    Guggenheim Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Raises Target Price to $224
    Market Newswire · 2026/11/4
  • Rating change
    Canaccord Genuity Maintains Buy on Neurocrine Biosciences, Raises Price Target to $220
    Benzinga · 2026/11/3
  • Company notice
    Neurocrine Biosciences | 4: Statement of changes in beneficial ownership of securities-Officer ROBERTS EIRY
    SEC · 2026/11/6
  • Company notice
    Neurocrine Biosciences | 4: Statement of changes in beneficial ownership of securities-Director LYONS GARY A
    SEC · 2026/11/20
  • Revenue Beat: Neurocrine Biosciences, Inc. Exceeded Revenue Forecasts By 7.6% And Analysts Are Updating Their Estimates
    Simply Wall St · 2026/11/5
  • Rating change
    Deutsche Bank Raises Price Target on Neurocrine Biosciences to $175 From $165, Keeps Hold Rating
    MT Newswires · 2026/11/3
  • Rating change
    RBC Lifts Price Target on Neurocrine Biosciences to $190 From $187, Keeps Outperform Rating
    MT Newswires · 2026/11/3
  • Neurocrine Biosciences Releases Findings From New Survey Showing Adults With Tardive Dyskinesia Reported Fewer Disruptions To Work, School After Starting Treatment With INGREZZA Capsules
    Benzinga · 2026/11/5
  • Rating change
    A Quick Look at Today's Ratings for Neurocrine Biosciences(NBIX.US), With a Forecast Between $175 to $230
    Market Newswire · 2026/11/4
  • Form 144 | Neurocrine Biosciences(NBIX.US) Insider Proposes to Sell 8.97 Million in Common Stocks
    Market Newswire · 2026/11/11
  • Company notice
    Neurocrine Biosciences | 144: Notice of proposed sale of securities pursuant to Rule 144
    SEC · 2026/11/18
  • Neurocrine Biosciences to Present at the 2026 Jefferies Global Healthcare Conference
    PR Newswire · 2026/11/11
  • Rating change
    Bernstein Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $218
    Market Newswire · 2026/11/5
  • Rating change
    Morgan Stanley Maintains Equal-Weight on Neurocrine Biosciences, Raises Price Target to $185
    Benzinga · 2026/11/4
  • Company notice
    Neurocrine Biosciences | 144: Notice of proposed sale of securities pursuant to Rule 144
    SEC · 2026/11/11
  • Rating change
    J.P. Morgan Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating
    Market Newswire · 2026/11/3
  • Rating change
    Morgan Stanley Maintains Neurocrine Biosciences(NBIX.US) With Hold Rating, Raises Target Price to $185
    Market Newswire · 2026/11/3
  • Rating change
    Guggenheim Maintains Buy on Neurocrine Biosciences, Raises Price Target to $224
    Benzinga · 2026/11/4
  • Morgan Stanley Maintains Neurocrine Biosciences(NBIX.US) With Hold Rating, Raises Target Price to $191
    Market Newswire · 2026/11/13
  • Company notice
    Neurocrine Biosciences | 4: Statement of changes in beneficial ownership of securities-Director MORROW GEORGE J
    SEC · 2026/11/4
  • Rating change
    Morgan Stanley Maintains Neurocrine Biosciences(NBIX.US) With Hold Rating, Maintains Target Price $183
    Market Newswire · 2026/11/3
  • Company notice
    Neurocrine Biosciences | 144: Notice of proposed sale of securities pursuant to Rule 144
    SEC · 2026/11/3
  • Rating change
    Needham Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $204
    Market Newswire · 2026/10/16
  • Company notice
    Neurocrine Biosciences | 8-K: Neurocrine Biosciences Reports Third-Quarter 2026 Financial Results
    SEC · 2026/11/3
  • Rating change
    Wedbush Cuts Price Target on Neurocrine Biosciences to $186 From $194, Keeps Outperform Rating
    MT Newswires · 2026/10/19

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 20:02:19 · For reference only, not investment advice and not tailored to your situation.

Neurocrine Biosciences discussion 0 comments

Add a comment